Skip to main content
QuestionsResearchTagsGuidelinesLeaderboard
tachyDx Research Portal

Research tagged [oncology]

Every paper is generated from a real clinical discussion on tachyDx, peer-reviewed by verified physicians, and published with a unique TDX identifier. All contributors are credited.

DOIs registered viaCrossref
Published26Under ReviewFlagged
Clear filters

5 papers

TDX-2026-00024

Optimal Sequencing of Immunotherapy for Pediatric B-Cell Acute Lymphoblastic Leukemia with Second Relapse Post-Allogeneic Hematopoietic Stem Cell Transplantation: A Clinical Consensus

Pediatric B-cell acute lymphoblastic leukemia (B-ALL) with second relapse following allogeneic hematopoietic stem cell transplantation (allo-HSCT) represents a highly challenging clinical scenario with limited curative options. This paper synthesizes expert clinical opinion regarding the optimal sequencing and selection of novel immunotherapies, specifically tisagenlecleucel (CAR-T cell therapy) and blinatumomab (CD19/CD3 bispecific T-cell engager), for a 6-year-old female presenting with a second marrow relapse 14 months post-transplant. The discussion addresses critical considerations including blast burden management, manufacturing timelines, and potential toxicities in a heavily pre-treated patient. A consensus emerged favoring a strategy of bridging with blinatumomab to reduce blast burden, followed by definitive tisagenlecleucel. This approach leverages the immediate availability and debulking potential of blinatumomab to optimize conditions for CAR-T cell therapy, which offers superior long-term remission rates. The paper also explores the role of inotuzumab ozogamicin and discusses logistical challenges in diverse healthcare settings. This synthesis provides practical guidance for clinicians navigating complex treatment decisions in this ultra-high-risk patient population, emphasizing evidence-based sequencing to maximize therapeutic efficacy and minimize adverse events.

A physician-only Q&A platform where verified medical doctors share clinical knowledge, debate evidence, and build the knowledge base the world needs.

Powered by

Platform

  • Questions
  • Research
  • Tags
  • Guidelines
  • Leaderboard
  • Report a Bug

Ecosystem

  • Teams
  • Sponsors
  • Hiring
  • Publishing
  • CME
  • Data

Company

  • About
  • Support
  • Privacy Policy
  • Terms of Service
  • Contact

© 2026 Aethryva Deeptech Pvt Ltd. All rights reserved.

Crossref Member
2 contributors 65 votes 9 Apr 2026

TDX-2026-00022

Management of Probable Invasive Aspergillosis in Febrile Neutropenia in Resource-Variable Settings: A Synthesis of Expert Opinion and Pragmatic Strategies

Invasive aspergillosis (IA) represents a significant cause of morbidity and mortality in immunocompromised patients, particularly those with febrile neutropenia following intensive chemotherapy for acute myeloid leukemia. Current international guidelines advocate for voriconazole as first-line therapy for probable IA. However, the implementation of these recommendations is frequently challenged in resource-variable settings due to high drug costs, limited availability of advanced formulations, and lack of therapeutic drug monitoring (TDM) capabilities. This paper synthesizes expert clinical perspectives from a peer-vetted medical Q&A platform to address the practical dilemmas encountered in such environments. We explore the nuanced decision-making process concerning initial antifungal choice, the role of conventional amphotericin B deoxycholate with pragmatic modifications, and the criteria for escalating to combination therapy. The discussion highlights the critical need for context-specific strategies that balance evidence-based medicine with economic realities, aiming to optimize patient outcomes despite significant resource constraints. This synthesis provides valuable insights for clinicians navigating these complex scenarios.

2 contributors 75 votes 9 Apr 2026

TDX-2026-00018

Immune Checkpoint Inhibitor Rechallenge After Grade 3 Myocarditis in Metastatic Melanoma: A Community Peer-Reviewed Clinical Consensus and Management Framework

Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy, yet they are associated with immune-related adverse events (irAEs), including potentially fatal myocarditis. Current guidelines universally recommend permanent discontinuation of ICIs following grade 3 or 4 myocarditis. This consensus paper addresses the critical clinical dilemma of managing progressive metastatic melanoma in a patient who achieved an excellent initial response to pembrolizumab but subsequently developed grade 3 myocarditis, which fully resolved. Utilizing a community peer-review platform involving two expert oncologists and 91 peer votes, a nuanced framework for considering ICI rechallenge was developed. The framework emphasizes stringent criteria, including complete resolution of myocarditis, lack of alternative effective therapies, and life-threatening cancer with prior ICI response, alongside comprehensive patient counseling and intensive cardio-oncology monitoring. Strategies discussed include switching to anti-CTLA4 monotherapy, reduced-dose anti-PD1 rechallenge, and the potential role of prophylactic abatacept or pre-rechallenge endomyocardial biopsy. While acknowledging the significant risks, including a reported 30-60% recurrence rate of myocarditis, the consensus highlights that in highly selected cases with limited alternatives, a carefully managed rechallenge may be considered under strict multidisciplinary oversight. This paper provides an evidence-informed approach to navigate this complex clinical scenario, balancing oncologic benefit with critical cardiac safety.

2 contributors 91 votes 9 Apr 2026

TDX-2026-00011

Management of Incidental Part-Solid Pulmonary Nodules: A Community-Based Clinical Consensus on Fleischner 2017 Guidelines and PET-CT Utility

Background: Incidental pulmonary nodules are frequently detected on computed tomography (CT) scans performed for unrelated indications, posing a significant clinical challenge regarding their malignant potential and appropriate management. Part-solid nodules, in particular, carry a higher risk of malignancy compared to pure ground-glass or solid nodules, necessitating careful surveillance strategies. The Fleischner Society 2017 guidelines provide evidence-based recommendations for their management, yet clinical scenarios often present nuances that require expert interpretation and communication. Methods: This study synthesizes expert opinions from a peer-reviewed clinical Q&A platform (tachyDx), involving two verified physicians (a radiologist and a pulmonologist) and 43 community peer votes. A specific clinical case of a 48-year-old non-smoker with an incidental 7mm part-solid pulmonary nodule (4mm solid component) was presented to elicit consensus on guideline adherence, solid component thresholds for intervention, utility of PET-CT, and inter-specialty communication. Results: A strong consensus emerged for strict adherence to Fleischner 2017 guidelines for initial surveillance of sub-centimeter part-solid nodules with small solid components. The solid component size was identified as the primary determinant for risk stratification, with PET-CT deemed unhelpful for sub-centimeter lesions due to resolution limitations. Emphasis was placed on clear, structured communication of findings and the importance of early shared decision-making to address patient anxiety. Conclusions: The findings underscore the critical role of Fleischner 2017 guidelines in managing incidental part-solid pulmonary nodules. They highlight the limited utility of PET-CT for sub-centimeter lesions and advocate for patient-centered communication strategies, integrating clinical judgment with established guidelines.

2 contributors 43 votes 6 Apr 2026

TDX-2026-00008

Management of Steroid-Refractory Immune Checkpoint Inhibitor-Associated Hepatitis: A Multidisciplinary Clinical Consensus and Case Report

Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy but are associated with immune-related adverse events (irAEs), including hepatitis. Management of steroid-refractory ICI-associated hepatitis presents a significant clinical challenge. This paper synthesizes expert opinion from a peer-reviewed clinical discussion platform, augmented by established medical literature, to provide guidance on managing a case of Grade 3 nivolumab-induced hepatitis refractory to initial corticosteroid therapy. **Methods:** A clinical scenario detailing a 62-year-old male with nivolumab-induced Grade 3 steroid-refractory hepatitis was posted on a specialized physician-to-physician Q&A platform (tachyDx). Two verified physicians, an oncologist and a gastroenterologist/hepatologist, contributed expert responses, which garnered 62 community peer votes. These responses were analyzed and integrated with current evidence-based guidelines and landmark clinical trials. **Results:** Consensus recommendations included mycophenolate mofetil (MMF) as the preferred second-line immunosuppressant, with tacrolimus as a potential addition for further refractory cases. Liver biopsy was deemed essential in steroid-refractory settings to confirm diagnosis and exclude alternative etiologies. Rechallenge with the same ICI for Grade 3 hepatitis was generally not recommended due to high recurrence rates. Management of the underlying non-small cell lung cancer (NSCLC) involved bridging chemotherapy while immunosuppression was ongoing. **Conclusions:** This case highlights the critical need for a multidisciplinary approach to steroid-refractory ICI-associated hepatitis. Early initiation of second-line immunosuppression, guided by liver biopsy, and careful consideration of cancer therapy continuation are paramount for optimizing patient outcomes.

2 contributors 62 votes 6 Apr 2026
Page 1 of 2Next →

Topics

Allpharmacology8critical-care7cardiology6emergency-medicine6oncology5pulmonology5nephrology4neurology4gastroenterology3immunology3hematology3infectious-disease3surgery3radiology2endocrinology2anesthesiology2hepatology2pediatrics2rheumatology2evidence-based-medicine1orthopedics1trauma1neonatology1psychiatry1internal-medicine1